Physician profile
James P Gray
NPI 1962675462
$8,464.79
in general payments reported to CMS, 2019-2025
27 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,477 · 2020: $905 · 2021: $1,374 · 2022: $1,050 · 2023: $522 · 2024: $588 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,767.45 | 2019-2020 | |
| Medtronic, INC. | $1,535.06 | 2021-2024 | Linq II |
| Novartis Pharmaceuticals Corporation | $934.31 | 2019-2025 | |
| Biotronik INC. | $631.91 | 2022-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Edora 8 Dr-T |
| Regeneron Healthcare Solutions, INC. | $248.31 | 2019-2024 | Evkeeza |
| Amgen INC. | $225.20 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $153.52 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Impulse Dynamics (USA) INC. | $132.74 | 2022-2025 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.47 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals, Ltd. | $80.35 | 2021-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $77.76 | 2019-2025 | Eliquis |
| Amarin Pharma, INC. | $67.06 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $65.54 | 2024-2025 | Amvuttra |
| Irhythm Technologies, INC. | $61.01 | 2022-2023 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $53.11 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.42 | 2023-2024 | Rybelsus, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $42.33 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $36.91 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $35.52 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $35.26 | 2019-2022 | |
| Abbott Laboratories | $28.82 | 2019 | |
| Baxter Healthcare | $25.51 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Ionis Pharmaceuticals, INC. | $24.48 | 2025 | Tryngolza |
| Gilead Sciences, INC. | $21.56 | 2019 | |
| Cvrx, INC. | $19.01 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.30 | 2022 | |
| Pfizer INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.